- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 4.4 Form of Amended and Restated Note Under the Securities Purchase Agreement
- 4.5 Form of Amended and Restated Pik Note Under the Securities Purchase Agreement
- 4.17 Ninth Amendment of Rights
- 10.4.1 Current Schedule Indentifying the Directors and Executive Officers
- 10.10.2 Second Amendment to Employment Agreement for Shalini Sharp
- 10.11.2 Second Amendment to Employment Agreement for Kerry Wentworth
- 10.12.2 Second Amendment to Employment Agreement for Garo Armen
- 10.20.2 Second Amendment to Employment Agreement for Karen Valentine
- 10.37 Securities Exchange Agreement by and Between Agenus Inc. and Invus Public
- 10.38 Securities Exchange Agreement by and Between Agenus Inc. and Bruce Fund Inc.
- 10.39 Securities Exchange Agreement by and Between Agenus Inc. and Professional Life
- 10.40 Securities Repurchase Agreement by and Between Agenus Inc. and Ingalls & Snyder
- 10.41 Securities Exchange Agreement by and Between Agenus Inc. and Ingalls & Snyder
- 21 Subsidiaries of Agenus Inc.
- 23 Consent of KPMG LLP, Independent Registered Public Accounting Firm
- 31.1 Certification of CEO Pursuant to Section 302
- 31.2 Certification of CFO Pursuant to Section 302
- 32.1 Certification of CEO and CFO Pursuant to Section 906
Exhibit 32.1
Certification
Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report on Form 10-K of Agenus Inc. (the “Company”) for the year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned to his/her knowledge hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(i) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(ii) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ GARO H. ARMEN |
Garo H. Armen, Ph.D. |
Chief Executive Officer |
/s/ SHALINI SHARP |
Shalini Sharp |
Chief Financial Officer |
Date: March 16, 2011
A signed original of this written statement required by Section 906 has been provided to Antigenics Inc. and will be retained by Agenus Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2010 and should not be considered filed as part of the Annual Report on Form 10-K.